Merck & Co., Inc. $MRK Stake Boosted by Norris Perne & French LLP MI

Norris Perne & French LLP MI boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 114.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 311,151 shares of the company’s stock after acquiring an additional 166,034 shares during the quarter. Merck & Co., Inc. accounts for approximately 2.0% of Norris Perne & French LLP MI’s portfolio, making the stock its 13th largest position. Norris Perne & French LLP MI’s holdings in Merck & Co., Inc. were worth $45,213,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $27,000. Curry Webb Wealth Management LLC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $29,000. Horizons Wealth Management bought a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $30,000. Graney & King LLC increased its holdings in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $41,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
• Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
• Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
• Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. HSBC increased their price target on Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Wells Fargo & Company raised their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Citigroup lifted their price objective on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research report on Monday, October 12th. Cantor Fitzgerald upped their price objective on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Finally, Morgan Stanley dropped their price objective on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 7th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $151.92.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP David Maraldo sold 18,706 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 in the last 90 days. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Trading Down 1.4%

Shares of MRK stock opened at $145.25 on Friday. The firm has a 50 day moving average price of $146.98 and a two-hundred day moving average price of $130.17. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $358.35 billion, a PE ratio of 116.20, a price-to-earnings-growth ratio of 6.74 and a beta of 0.21. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the previous year, the company posted $2.13 earnings per share. The business’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts predict that Merck & Co., Inc. will post 2.64 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.